Last reviewed · How we verify
Depo-subQ 104
At a glance
| Generic name | Depo-subQ 104 |
|---|---|
| Also known as | depo-subQ provera 104®, Medroxyprogesterone acetate injectable suspension, Depo-subQ Provera 104® |
| Sponsor | FHI 360 |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age (PHASE1)
- A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046 (PHASE1)
- Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood (PHASE4)
- Study of Self or Clinic Administration of DepoProvera (NA)
- Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods (PHASE1)
- Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis (PHASE2)
- Lower Dose Depo Provera® Contraceptive Injection (PHASE1)
- Long-Acting Reversible Contraception (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |